Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Other Non-Current Assets (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Other Non-Current Assets data on record, last reported at $3.3 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 16.66% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, down 16.66%, while the annual FY2025 figure was $3.3 million, 16.66% down from the prior year.
  • Other Non-Current Assets reached $3.3 million in Q4 2025 per TRDA's latest filing, down from $4.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $13.8 million in Q1 2023 and bottomed at $199000.0 in Q2 2025.
  • Average Other Non-Current Assets over 4 years is $3.5 million, with a median of $4.0 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Assets: plummeted 81.11% in 2024, then soared 429.49% in 2025.
  • A 4-year view of Other Non-Current Assets shows it stood at $5.2 million in 2022, then plummeted by 46.45% to $2.8 million in 2023, then skyrocketed by 41.58% to $4.0 million in 2024, then dropped by 16.66% to $3.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $3.3 million in Q4 2025, $4.0 million in Q3 2025, and $199000.0 in Q2 2025.